A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. by Minhinnick, A, Satti, I, Harris, S, Wilkie, M, Sheehan, S, Stockdale, L, Lopez-Ramon, R, Poulton, I, Lawrie, A, Vermaak, S, Le Vert, A, Del Campo, J, Hill, F, Moss, P, McShane, H, Manjaly Thomas, Z